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Summary 
 
Infective endocarditis (IE) is a rare, but severe and potentially life-threatening 
complication of congenital heart disease (CHD), both during its natural course and 
after cardiac surgery for CHD. Although antibiotic therapy is available for the 
prevention and for the treatment of IE, the frequency of IE in patients with CHD is still 
increasing during the past decades. The reasons for this trend are not completely 
understood in patients with CHD. Therefore, the first part of this work analyses 
potential factors influencing the increasing frequency of IE in CHD.  
Prevention of IE is mainly focused on antibiotic endocarditis prophylaxis (AEP), 
whose benefit has been questioned in the past. Therefore, the second part of this 
work analyses potential factors contributing to the prevention of IE in patients with 
CHD.  
For this analysis different clinical studies were performed either using a retrospective 
or a prospective design. An interdisciplinary approach was primarily designed with 
consideration of the complexity of the treatment of patients with CHD as well as the 
prevention of IE. Therefore, in different single- and multi-centre clinical trials, the 
frequency, clinical course and complications of IE were described and potential risk 
factors for IE were analysed. Emphasis was upon all age groups of patients treated 
for CHD from the newborn to the adult. The impact of foreign material implanted 
during cardiac surgery or catheter-guided interventions, and the impact of dental 
health of children, adolescents and young adults grown up with congenital heart 
disease (GUCH) for the risk of IE were additional research topics.  
As a consequence of improved paediatric cardiology management and cardiac 
surgery, our results show that even patients with complex types of CHD frequently 
survive until adulthood, but remain at lifelong risk for IE. Cardiac surgery, especially 
for complex types of CHD, often requires the implantation of foreign material such as 
cardiovascular devices. In two studies we point out that the spectrum of infected 
cardiovascular devices includes biological (homografts, xenografts, or patches) as 
well as synthetic materials (vascular shunts, mechanical heart valve, or pacemaker 
leads). Therefore, the use of cardiovascular devices generates a new type of IE, 
defined as cardiovascular device related infections (CVDRI). Indeed, one of our new 
findings is that the implantation of cardiovascular devices is a significant risk factor 
for IE in paediatric patients with CHD as well as in GUCH patients. The clinical 
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spectrum and complications of CVDRI are similar with native IE, but our analysis 
indicates that CVDRI is often associated with staphylococci as typical for 
postinterventional IE, in contrast to native IE, where streptococci are more frequent. 
For treatment of CVDRI secondary cardiac surgery is nearly always performed due to 
the need of ex-plantation of infected cardiovascular devices, because staphylococci 
are capable to colonize on foreign material surfaces of cardiovascular devices and 
are difficult to treat with antibiotics alone.  
As a further new aspect of IE in CHD our studies prodded to the fact that GUCH 
patients represent a new patient population, who remain at risk for IE during their live 
due to the consequences of cardiac surgery. The impact of cardiac and extra-cardiac 
complications during clinical course of IE in CHD could be demonstrated for children 
as well as for GUCH patients. The high number of cardiac complications requires 
secondary cardiac re-operation, while embolic complications leading to neurological 
sequels result in a high frequency secondary co-morbidity. 
Regarding the prevention of IE, we could show that the level of dental health in 
children with CHD is low due to a high rate of caries, gingival affections and 
deciduous and permanent teeth lacked of adequate treatment. GUCH patients 
requiring dental procedures are at risk for IE and may suffer from severe 
complications of IE. Furthermore, there is evidence that the prevention of IE is limited 
to the compliance, practice and knowledge of the patients, the parents, and the 
involved physicians. The interdisciplinary infectious control during postoperative 
course has to be considered for the prevention of IE and underlines the complexity of 
patients with complex type of CHD.  
Therefore, complete resolution of haemodynamic disturbances associated with CHD 
should be strived for, especially in a population of patients surviving until adulthood. 
This could be shown in our study of percutaneous closure of patent ductus arteriosus 
in small infants with high complete closure rate of patent ductus arteriosus without 
any postinterventional IE.  
In 2007 the American Heart Association published new recommendations of AEP. 
They prioritise AEP only for dental/oral procedures in patients with underlying cardiac 
conditions at the highest risk for a severe morbid outcome as a consequence of IE. 
Furthermore, the new recommendations emphasize on the importance of promoting 
good dental health in the prevention of IE. This is in accordance with the results of 
this work, which in conclusion emphasizes on the impact of foreign material for IE, 
 5
which characterize patients at high risk of IE, as well as on the on the impact of 
dental health in children and GUCH patients at risk for IE.  
In the future, clinical and epidemiological studies have to show, whether these 
changes of the recommendations of AEP are adequate to prevent IE in patients with 
CHD sufficiently. Further research has to focus on the impact of foreign material, 
which should be diminished either by complete endothelialization of the 
cardiovascular devices or even better by partial or complete biological absorption of 
the foreign material and replacement of healthy native tissue during a natural healing 
process. The GUCH patients at risk of IE have to be supervised by an 
interdisciplinary infectious prevention control. 
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CVDRI Cardiovascular device related infection 
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1. Introduction 
 
Congenital heart disease (CHD) includes various types of inborn intra- and extra-
cardiac malformations of the human heart. Between 0.6 and 0.9 of 1000 neonates 
are born with CHD. Therefore, CHD represents the most frequent type of organ 
malformations in human beings [1, 2]. 
Diagnostic and therapeutic approaches to CHD have developed tremendously during 
the past century. Diagnosis of CHD can be made easily even before birth using foetal 
echocardiography, which may determine therapy immediately after birth. Therapeutic 
options for CHD imply medical therapy as well as invasive interventions, in some by 
cardiac surgery, but to an increasing extent by percutaneous catheter-guided intra- 
and extra-cardiac procedures. 
Meanwhile, the survival of patients grown up with congenital heart disease (GUCH) 
has substantially improved to more than 95% [3]. This is associated with an 
acceptable quality of life, even in the most complex type of CHD such as uni-
ventricular malformations reaching adulthood by palliation with the Fontan procedure 
[1]. Therefore, the number of adults with CHD presently exceeds the number of 
paediatric patients with CDH [4, 5].  
One of the most important pathophysiologic changes in patients with CHD is the 
haemodynamic impairment of blood flow within the heart during passage through the 
four cardiac valves, or outside the heart in the great arteries, respectively. This 
pathologic blood flow can be localized at the valvular level, such as a dysplastic 
aortic valve stenosis, at an intra-cardiac site, such as in ventricular septal defects, or 
at an extra-cardiac site, like patent arterial duct. Under physiologic conditions the 
normal blood flow across a heart valve is laminar, but the blood flow is severely 
disturbed in either stenotic or regurgitant heart valves, or intra- or extracardiac 
shunts, respectively. The laminar blood flow is changed to turbulent blood flow and 
shear stress impairs the integrity of the endocardiac surface of the heart valves and 
the mural endocardium, as well as the endothelial surface of the great arteries by. 
The injury of the endocardium and endothelium is associated with an inflammatory 
tissue reaction. Such lesions can only be partially healed and therefore represent the 
pre-requisite of an endocardial infection. This first pathogenetic step to an infective 
endocarditis (IE) is called nonbacterial thrombotic endocarditis (NBTE). 
Subsequently, transient bacteraemia induced either by daily oral care activities, such 
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as chewing, tooth-brushing, or by different types of medical diagnostic and 
therapeutic invasive procedures, such as dental care or appendectomy, may 
secondarily infect NBTE and the clinical entity of IE runs its course [6]. 
In the developed countries, IE is most frequently associated with CHD in childhood. 
Its spectrum of clinical signs and complications ranges from oligo-symptomatic 
unspecific courses, which can be cured by antibiotic therapy without residua, to 
severe complicated courses associated with deleterious cardiovascular 
complications, like embolic events affecting extra-cardiac sites (brain, lung, kidney, 
muscular-skeletal, extremities), even with lethal outcome. 
In childhood, IE can occur in non-operated congenital valvular disease as well as in 
an operated heart valve after cardiac surgery (Figure 1) [7-39].  
 
 
Figure 1. Localisation of infective endocarditis in children with congenital heart disease. Data of the 
frequency of affected heart structures are calculated in a meta-analysis of clinical studies [8-39], taken 
from Knirsch W, Nadal D. Infective endocarditis in congenital heart disease – From the neonate to the 
adult. In preparation [40]. 
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Therefore, IE may present as a complication of the natural course of CHD or as a 
consequence of treatment of CHD.  
Although diagnosis, treatment, and outcome of IE significantly improved during the 
past century, the incidence of IE in childhood increased with a rate up to 1.35 
patients per 1,000 paediatric hospital admissions (Figure 2) [7]. The causes for the 
increasing incidence of IE in patients with CHD are not completely understood.  
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Figure 2. Frequency and overall mortality of paediatric IE are shown in the context of the available 
antibiotic treatment and the development of surgical and interventional catheter therapy for CHD 
during the past century in the developed countries. Data are retrieved from a meta-analysis of clinical 
studies [8-39], taken from Knirsch W, Nadal D. Infective endocarditis in congenital heart disease – 
From the neonate to the adult. In preparation [40]. 
 
On the other hand, different measures are available to prevent IE as a severe, life-
threatening complication of CHD, such as antibiotic endocarditis prophylaxis (AEP) to 
reduce the amount of transient bacteraemia [41]. The benefit of AEP has been 
questioned in the past and the reasons for the failure to prevent of IE in some 
patients with CHD also remain unclear. 
Therefore, the aim of this work was (1) to investigate potential factors responsible for 
the increasing incidence of IE in CHD, and (2) to analyse preventive strategies to 
overcome this problem in the future. 
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2.  Reasons for the increasing frequency of infective endocarditis 
 
2.1 New group of patients grown up with congenital heart disease 
 
The survival of patients with CHD has increased during the past four decades due to 
the enormous success of paediatric cardiology, and cardiac surgery. Milestones of 
this development are the Rashkind atrioseptostomy, the implementation of 
prostaglandin therapy of ductus-dependent blood flow types of CHD, 
echocardiography and magnetic resonance imaging as the most important diagnostic 
tools, the ongoing refinement of cardio-surgical techniques, including optimisation of 
bypass techniques, and of intra-operative anaesthesia and postoperative intensive 
care management. This creates the expectancy that patients even with the most 
complex types of CHD at least can survive until adulthood [3]. Therefore, a new 
population of patients grown up with CHD (GUCH) has been determined either as 
adolescents or adults with CHD. But, despite an increasing life expectancy in GUCH 
patients, most of these young adults live with residual haemodynamic cardiac lesions 
and therefore carry a potential life-long risk for IE. New aspects concerning impact of 
IE for GUCH patients has been analysed by the author [42] (Appendix I): 
 
In a retrospective single-centre clinical study we focused on the epidemiology, 
spectrum of pathogens, and clinical presentation of GUCH patients. We could 
demonstrate that IE in GUCH patients is a rare condition, but often associated with a 
high rate of embolic complications (30.8%), a high number of unknown sources of 
preceding bacteraemias (Figure 3), a high demand for secondary cardiac surgery 
during (11.5%) and after (55.8%) IE and a decreasing overall mortality rate [42] 
(Appendix I).  
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Figure 3. Predisposing risk factors for IE in patients grown up with CHD [42] (Appendix I). 
 
 
2.2 New treatment options using cardiovascular devices 
 
The surgical therapy of CHD includes both, the palliation or complete correction of 
CHD. But often these intra- or extra-cardiac surgical procedures require the 
implantation of foreign material in terms of cardiovascular devices. This foreign 
material is derived from synthetic material such as Goretex tube grafts for shunt 
procedures, and biological sources such as homografts for replacement of atretic 
valves. Therefore, acutely during the postoperative course, or chronically during long 
term follow up, the implanted foreign material represents the potential nidus for a 
NBTE. Therefore, cardiovascular device related infections (CVDRI) represent a new 
type of IE, which can be generally defined as an infection of temporarily or 
permanently implanted cardiac or vascular devices [43]. In paediatric patients the 
importance of foreign material as a risk factor for IE could be demonstrated for 
permanent pacemaker systems, different materials implanted during cardiac surgery, 
and recently also during interventional catheter procedures [44] (Appendix II):  
 
The impact of foreign material for IE was analysed in a retrospective single-centre 
clinical study in the University Children’s Hospital Zurich. Covering a time period of 
10 years the diagnosis of IE in our cohort was made in 0.36% of children aged less 
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than 18 years, who have been treated for CHD. The main results excluded cardiac 
intervention by itself as a risk factor for IE, while cardiac intervention with the use of 
foreign material increased the risk for IE (Figure 4). Trans-venous pacemaker 
implantation had the highest risk for IE. Staphylococci were the most frequently 
isolated pathogens [44] (Appendix II). 
 
 
Figure 4. Foreign material is a significant risk factor for IE in patients with CHD. The odds ratios for the 
risk for infective endocardits with a 95% confidence level (95% CI) in the different groups are shown. 
[44] (Appendix II). 
 
 
2.3 Changing environmental factors 
 
Diagnostic and therapeutic procedures can cause the potential risk for IE caused by 
transient bacteraemia. By disturbing the integrity of the otherwise intact cutaneous 
and mucocutaneous barrier to the physiologic bacterial flora, pathogens like 
streptococci and staphylococci may invade the blood and potentially infect pre-
existing NBTE lesions of the endocardium. Dental procedures are the most frequent 
preceding events leading to bacteraemia and IE [42] (Appendix I) and also have 
been described as a severe complication in GUCH patients [45]: 
The aim of this retrospective single-centre study was to determine the incidence of IE 
following dental procedures in adults with CHD, and to assess correlations with AEP. 
During a one-year period 456 patients aged > 16 years treated for CHD were 
interviewed about their knowledge of AEP against IE. The need of AEP was known 
by 78%. Three patients (0.2%) developed IE during the observation period 11 to 16 
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days after dental scaling was performed without AEP. Although the patients 
presented the leaflet with recommendations for prophylaxis, the dentists refused to 
prescribe antibiotics in these cases. One patient developed a severe cerebral 
abscess. It was concluded that optimising information to dentists may improve 
prophylaxis for IE [45]. 
 
Primary dental health seems to be of utmost importance in reducing the risk of 
bacteraemia either during daily oral care activities or during high risk medical 
procedures. The link between dental health and children with CHD was described in 
an outpatient clinic for paediatric cardiology in cooperation with the department of 
paediatric dentistry at the University of Berlin [46]. 
Children and adolescents with CHD were evaluated in a prospective single-centre 
clinical trial performed by paediatric cardiologists in cooperation with the local 
department of paediatric dentistry. 163 patients of the in- and out-patient department 
in a tertiary care heart centre were screened for their nutritional behaviour, oral and 
dental health care, and compliance of AEP. These data were correlated with the 
dental health measured parameters using the plaque, gingival and caries dental 
indices. Cardiac risk factors were cyanosis (12%), previous cardiac operations 
(71%). Nutrition and dental risk factors were feeding with sweet drinks (78%), and 
abandonment of fluoride substitution (24%). Factors compromising the compliance of 
AEP for IE were lack of delivered leaflets containing recommendations for 
prophylaxis of the paediatric cardiologists (7%), leaflet not presented to the dentist by 
the parents or the patient (33%), and refusal of AEP prior to dental treatment by the 
dentists (42%). These results were associated in the investigated patients with a high 
number of carious primary teeth (87%) and carious secondary teeth (46%), which 
needed immediate dental therapy. We concluded that the antibiotic prophylaxis for IE 
has to be optimized, and the primary-primary prophylaxis of the complete family living 
with a child affected by CHD should be performed to ensure complete oral health 
[46]. 
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3. New aspects to prevent infective endocarditis 
 
3.1 Antibiotic endocarditis prophylaxis 
 
Prevention can be defined as any medical activity or public health procedure 
intended to prevent a disease, rather than to cure it by reducing its morbidity and 
mortality.  
Preventive measures can be divided into primary prophylaxis (prevention of the 
development of a disease), secondary prophylaxis (screening at an early stage to 
prevent or delay progression of the disease), and tertiary prophylaxis (reduction of 
the negative impact of an established disease by restoring function and overcome 
disease related complications) [47].  
AEP is the most frequently used measure to reduce known transient bacteraemia 
due to high risk procedures and is therefore an example for primary prevention. 
Although the efficacy of AEP has been questioned [41], its indication is widely 
accepted and frequently provided. The importance of dental health has been 
emphasized as a primary goal to prevent IE [41]. It is a reasonable goal in paediatric 
patients to prevent IE by optimizing the dental health in the complete family in which 
one member has CHD, which has been defined as primary-primary prophylaxis [46, 
48-49]. This can be achieved by close cooperation between paediatric cardiology and 
paediatric dentistry. 
Dental health seems to be of striking importance to reduce risk of bacteraemia either 
during daily oral care activities or during high risk medical procedures. The link 
between dental health and children with CHD has been investigated in an outpatient 
department for paediatric cardiology in cooperation with the department of paediatric 
dentistry at the Charité Berlin [46]. 
Nevertheless, prevention can fail due to different reasons. In case of AEP for IE we 
analysed the efficacy of AEP at different levels in children with CHD in three 
outpatient departments [50] (Appendix III): 
 
In a prospective multi-centre clinical trial we investigated 296 patients with CHD, 
aged between 4 weeks and 55.8 years, over a six month time period using an 18-
question survey pertaining to the practice of AEP. While most patients (91.6%) had 
acyanotic CHD, usually preoperative (45.3%), categorized as high risk for IE due to 
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previous IE (2.0%), cyanosis (8.4%), or prosthetic valves (5.4%) (Figure 5), potential 
sources for failure of AEP were found to be no existence of the wallet card containing 
the recommendations for AEP (6.8%), no communication between patient and 
physician during a visit (13.2%), and no sufficient inquiry by the physician before 
procedures performed (43.2%). The patients underestimated (4.4%) or had no 
knowledge of their individual risk for IE (37.5%), or underestimated the indication for 
AEP (11.1%). This results in a high refusal of AEP (60.5%) in a cohort of bad dental 
status with no previous dental therapy at all (35.5%), and a high rate of caries 
(17.2%) and gingivitis (7.4%). We concluded that AEP fails at different levels, i.e., 
patient, paediatric cardiologist, and dentist, and efforts have been proposed to 
optimize AEP [50] (Appendix III). 
 
 
Figure 5. Risk factors for IE due to the cardiac diagnosis [50] (Appendix III). 
 
 
3.2   Complete resolution of haemodynamic disturbances 
 
The definitive curative therapy of cardiac lesions with complete normalization of 
physiologic haemodynamics may be a further preventive strategy to overcome IE. 
Although the risk for IE may even be elevated compared to the non-operated state 
immediately after intervention if foreign material has to be implanted to cure cardiac 
lesions, e.g. intra- or extra-cardiac communications such as patent arterial duct, 
ventricular septal defects, and atrial septal defects, it is decreased to zero after three 
to six months following complete endothelialization of the implanted cardiac devices. 
The medical issues that should be addressed in the GUCH population can be 
characterized as residua (lesions intentionally left behind at the time of reparative 
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surgery) or sequalae (necessary consequences of reparative operations or the 
natural history of the lesions) [51]. 
The interventional closure of patent ductus arteriosus was reported as an example 
for complete resolution of haemodynamics and therefore complete elimination of the 
risk for IE and was made possible by a collaboration with four centres of Paediatric 
Cardiology in Switzerland and Germany [52] (Appendix IV): 
 
In a retrospective multi-centre observational study we evaluated the immediate and 
mid-term results of percutaneous closure of patent arterial duct in a subgroup of 
small infants of less than 8 kg body weight using different closure devices. Infective 
complications did not occur during follow up and complete closure was achieved in 
all patients after six months [52] (Appendix IV). 
 
 
3.3 Interdisciplinary approach to control infections 
 
The complexity of health care of patients with CHD and the prevention of acute 
infectious complications after cardiac surgery includes all involved subspecialities 
such as paediatric cardiology, paediatric cardiac surgery, paediatric cardiac 
anaesthesia, paediatric intensive care, paediatric infectious disease specialists, 
paediatric dentistry, both in the in-patient as well as the out-patient departments 
(Figure 6) [50] (Appendix III). This collaboration is challenging, but has to be 
performed in a multidisciplinary approach [44] (Appendix II). 
 
 
Figure 6. Distribution of the different subgroups of physicians involved in the performance of AEP 
children and adults with CHD [50] (Appendix III). 
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The difficulties in diagnosing early postoperative fungal infections despite IE leading 
to fatal aortic rupture has been shown as an example in a case report [53]: 
The fatal course of a Candida albicans mediastinitis after truncus arteriosus repair is 
described in a 4-year-old child leading to aortic rupture 3 weeks postoperatively 
(Figure 7). Although multidisciplinary efforts have been made for establishing early 
diagnosis and combined aggressive surgical and medical treatment was performed, 
all therapeutic efforts failed. Guidelines for the diagnosis and therapy in paediatric 
patients with rare postoperative complications are required [53]. 
 
 
Figure 7: Macroscopic finding of the ascending aorta. Lesion of the aortic wall (arrow) near the suture 
line, which was intact [53]. 
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4. Conclusions and future perspectives 
 
The main results of this work document that IE is still a complication in paediatric 
patients with CHD as well as in adults with CHD [42] (Appendix I). The risk profile of 
IE in CHD includes new types of infections associated with the implantation of 
different types of cardiovascular devices [44] (Appendix II). The CVDRI is caused 
either by invasive interventions of cardiac surgery or catheter related procedures [44] 
(Appendix II). The need for prevention with dental procedures is stressed in GUCH 
patients [45] as well as in paediatric patients [46], since these are among the most 
frequent invasive procedures and, therefore, important potential sources of transient 
bacteraemia. Despite the common use of AEP in high risk procedures to reduce the 
rate of bacteraemia, primary prophylactic strategies, leading to better oral-dental 
health have to be focused upon [50] (Appendix III). This approach seems to be more 
important due to the high rate of transient bacteraemias associated with daily oral 
care activities. Complete resolution of the haemodynamic disturbances without 
residua or sequalae after treatment has to be achieved to reduce the risk of IE to the 
natural risk of the healthy community [52] (Appendix IV). 
A multidisciplinary approach of infection control and guidelines focusing on the 
characteristics of IE in paediatric and adult patients are required [53]. 
The reasons for the increasing number of paediatric IE and ways to confront this 
trend cannot be answered completely in this work. Therefore, in the future different 
additional strategies have to be developed: 
Epidemiologic studies with prospective data survey of paediatric and adult patients 
with IE regarding incidence, risk factors, pathogenesis, type of CHD, microbiology, 
clinical manifestations and complications, diagnosis, therapy, and outcome seems to 
be most essential. Due to the rarity of IE in CHD multi-centre trials are needed. 
Future research must analyse the impact of different materials of cardiovascular 
devices and their potential risk for infection. Medical devices less prone to infection 
have to be designed. The efficacy of AEP after implantation of cardiovascular 
devices has to be analysed. 
By pursuing this work, the common goal to reduce IE as a complication of CHD can 
be achieved. 
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